Efficacy Endpoints with Secukinumab 150 mg at Week 260 (5 year)
| Variable | Secukinumab 150 mg1 | ||
| Total N = 106 | Anti–TNF-naïve N = 66 | Anti–TNF-IR N = 40 | |
| ASAS202 | 69.9 (83) | 73.7 (57) | 61.5 (26) |
| ASAS402 | 54.2 (83) | 63.2 (57) | 34.6 (26) |
| ASAS-Partial Remission2 | 25.3 (83) | 28.1 (57) | 19.2 (26) |
| BASDAI502 | 53.0 (83) | 56.1 (57) | 46.2 (26) |
| BASMI3 | -0.7±1.2 (80) | - | - |
| BASFI3 | -2.8±2.6 (83) | - | - |
| SF-36 PCS3 | 8.0±8.5 (79) | 8.5±8.9 (56) | 6.8±7.4 (23) |
Data are reported as observed; 1Includes placebo switchers; 2% responders (n); 3mean change from baseline ± SD (n); IR, inadequate response; N, total number of randomised patients; n, number of evaluable patients; TNF, tumour necrosis factor